Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review
Pancreatic Ductal Adenocarcinoma (PDAC) accounts for a significant burden of global cancer deaths worldwide. The dismal outcomes associated with PDAC can be overcome by detecting the disease early and developing tools that predict response to treatment, allowing the selection of the most optimal tre...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1555963/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710585046892544 |
|---|---|
| author | Ronit Juthani Ashish Manne |
| author_facet | Ronit Juthani Ashish Manne |
| author_sort | Ronit Juthani |
| collection | DOAJ |
| description | Pancreatic Ductal Adenocarcinoma (PDAC) accounts for a significant burden of global cancer deaths worldwide. The dismal outcomes associated with PDAC can be overcome by detecting the disease early and developing tools that predict response to treatment, allowing the selection of the most optimal treatment. Over the last couple of years, significant progress has been made in the development of novel biomarkers that aid in diagnosis, prognosis, treatment selection, and monitoring response. Blood-based biomarkers offer an alternative to tissue-based diagnosis and offer immense potential in managing PDAC. In this review, we have discussed the advances in blood-based biomarkers in PDAC, such as DNA (mutations and methylations), RNA, protein biomarkers and circulating tumor cells (CTC) over the last decade and also elucidated all aspects of practical implementation of these biomarkers in clinical practice. We have also discussed implementing multiomics utilizing more than one biomarker and targeted therapies that have been developed using these biomarkers. |
| format | Article |
| id | doaj-art-5547a446ca8d49ba8e4c735f96ab2935 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-5547a446ca8d49ba8e4c735f96ab29352025-08-20T03:14:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15559631555963Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a reviewRonit Juthani0Ashish Manne1Department of Medicine, Saint Vincent Hospital, Worcester, MA, United StatesDepartment of Internal Medicine, Division of Medical Oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United StatesPancreatic Ductal Adenocarcinoma (PDAC) accounts for a significant burden of global cancer deaths worldwide. The dismal outcomes associated with PDAC can be overcome by detecting the disease early and developing tools that predict response to treatment, allowing the selection of the most optimal treatment. Over the last couple of years, significant progress has been made in the development of novel biomarkers that aid in diagnosis, prognosis, treatment selection, and monitoring response. Blood-based biomarkers offer an alternative to tissue-based diagnosis and offer immense potential in managing PDAC. In this review, we have discussed the advances in blood-based biomarkers in PDAC, such as DNA (mutations and methylations), RNA, protein biomarkers and circulating tumor cells (CTC) over the last decade and also elucidated all aspects of practical implementation of these biomarkers in clinical practice. We have also discussed implementing multiomics utilizing more than one biomarker and targeted therapies that have been developed using these biomarkers.https://www.frontiersin.org/articles/10.3389/fonc.2025.1555963/fullpancreatic ductal adenocarcinomabiomarkersbloodDNARNAprotein |
| spellingShingle | Ronit Juthani Ashish Manne Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review Frontiers in Oncology pancreatic ductal adenocarcinoma biomarkers blood DNA RNA protein |
| title | Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review |
| title_full | Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review |
| title_fullStr | Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review |
| title_full_unstemmed | Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review |
| title_short | Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review |
| title_sort | blood based biomarkers in pancreatic ductal adenocarcinoma developments over the last decade and what holds for the future a review |
| topic | pancreatic ductal adenocarcinoma biomarkers blood DNA RNA protein |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1555963/full |
| work_keys_str_mv | AT ronitjuthani bloodbasedbiomarkersinpancreaticductaladenocarcinomadevelopmentsoverthelastdecadeandwhatholdsforthefutureareview AT ashishmanne bloodbasedbiomarkersinpancreaticductaladenocarcinomadevelopmentsoverthelastdecadeandwhatholdsforthefutureareview |